Literature DB >> 12952227

Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis.

K Ohshima1, K Karube, K Shimazaki, H Kamma, J Suzumiya, M Hamasaki, M Kikuchi.   

Abstract

The myelodysplastic syndromes (MDS) are a group of disorders characterized by peripheral pancytopenia despite normo- or hyper-cellular bone marrow. This is thought to be due to apoptosis of hematopoietic bone marrow cells, resulting in ineffective hematopoiesis. The heterogeneous nuclear ribonucleoprotein (hnRNP) B1 is involved in pre-mRNA processing and binds to telomeric cDNA repeats. The hnRNP B1 is a marker for early cancer. The aim of our study was to clarify the relationships between prognosis and apoptosis, telomerase activity (TA) and hnRNP expression in the bone marrow. The subjects were 51 patients with MDS, including patients with refractory anemia (RA) (n = 32), refractory anemia with ringed sideroblasts (RARS) (n = 1), refractory anemia with excess blasts (RAEB) (n = 7), refractory anemia with excess blasts in transformation (RAEB-t) (n = 8) and chronic myelomonocytic leukemia (CMMoL) (n = 3). We also studied 6 cases with acute myelogenous leukemia (AML) arising from MDS (AML-MDS) and 10 control subjects. Bone marrow biopsies were stained immunohistochemically for caspase-3 (marker of apoptotic activity) and human telomerase reverse transcriptase (hTERT), and hnRNP B1. Fatal pancytopenia was the cause of death in 19 of the 51 patients. The caspase-3 positive cell rate was higher in MDS (16.3%) than in controls (4.4%) and AML-MDS (0.5%). The percentage of hnRNP B1-positive cells was higher in MDS (15.3%) and AML-MDS (56.3%) than in controls (5.6%). In MDS, hnRNP B1 levels were higher in RAEB and RAEB-t subtypes than in RA and RARS. The percentage of hTERT-positive cells was higher in AML-MDS (50.0%) than in controls (20.2%) and MDS (23.6%). Our findings suggest that activation of apoptosis occurs in MDS in the absence of hTERT expression, implicating high apoptosis in the absence of high TA with ineffective hematopoiesis. Poor prognosis correlated with higher caspase-3 and lower hTERT rates. In MDS, hnRNP B1 activity may be associated with leukemic transformation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12952227     DOI: 10.1080/1042819031000083037

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.

Authors:  Li Zhou; Christine McMahon; Tushar Bhagat; Cristina Alencar; Yiting Yu; Melissa Fazzari; Davendra Sohal; Christoph Heuck; Krishna Gundabolu; Chun Ng; Yongkai Mo; Wa Shen; Amittha Wickrema; Guanghui Kong; Ellen Friedman; Lubomir Sokol; Ioannis Mantzaris; Giannis Mantzaris; Andrea Pellagatti; Jacqueline Boultwood; Leonidas C Platanias; Ulrich Steidl; Lei Yan; Jonathan M Yingling; Michael M Lahn; Alan List; Markus Bitzer; Amit Verma
Journal:  Cancer Res       Date:  2010-12-28       Impact factor: 12.701

2.  Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.

Authors:  Tony A Navas; Mani Mohindru; Myka Estes; Jing Ying Ma; Lubomir Sokol; Perry Pahanish; Simrit Parmar; Edwin Haghnazari; Li Zhou; Robert Collins; Irene Kerr; Aaron N Nguyen; Yin Xu; Leonidas C Platanias; Alan A List; Linda S Higgins; Amit Verma
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

3.  Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

Authors:  Li Zhou; Aaron N Nguyen; Davendra Sohal; Jing Ying Ma; Perry Pahanish; Krishna Gundabolu; Josh Hayman; Adam Chubak; Yongkai Mo; Tushar D Bhagat; Bhaskar Das; Ann M Kapoun; Tony A Navas; Simrit Parmar; Suman Kambhampati; Andrea Pellagatti; Ira Braunchweig; Ying Zhang; Amittha Wickrema; Satyanarayana Medicherla; Jacqueline Boultwood; Leonidas C Platanias; Linda S Higgins; Alan F List; Markus Bitzer; Amit Verma
Journal:  Blood       Date:  2008-05-12       Impact factor: 22.113

4.  miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.

Authors:  Tushar D Bhagat; Li Zhou; Lubomir Sokol; Rachel Kessel; Gisela Caceres; Krishna Gundabolu; Roni Tamari; Shanisha Gordon; Ioannis Mantzaris; Tomasz Jodlowski; Yiting Yu; Xiaohong Jing; Rahul Polineni; Kavi Bhatia; Andrea Pellagatti; Jacqueline Boultwood; Suman Kambhampati; Ulrich Steidl; Cy Stein; Wenjun Ju; Gang Liu; Paraic Kenny; Alan List; Markus Bitzer; Amit Verma
Journal:  Blood       Date:  2013-02-06       Impact factor: 22.113

5.  The role of apoptosis and current therapeutic challenges in myelodysplastic syndromes.

Authors:  M Diamantidis; S Dimoudis; Ph Klonizakis; K Badekas; K Koutourli; S Haralambidou-Vranitsa; E Ioannidou-Papagiannaki
Journal:  Hippokratia       Date:  2007-10       Impact factor: 0.471

6.  Telomerase detection in the diagnosis and prognosis of cancer.

Authors:  Eiso Hiyama; Keiko Hiyama
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

Review 7.  The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies.

Authors:  Stefan G C Mestrum; Anton H N Hopman; Frans C S Ramaekers; Math P G Leers
Journal:  Blood Adv       Date:  2021-04-13

8.  Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome.

Authors:  Hee Sue Park; Jungeun Choi; Cha Ja See; Jung Ah Kim; Si Nae Park; Kyongok Im; Sung Min Kim; Dong Soon Lee; Sang Mee Hwang
Journal:  Ann Lab Med       Date:  2017-05       Impact factor: 3.464

9.  Telomerase confers resistance to caspase-mediated apoptosis.

Authors:  Yira Bermudez; Diana Erasso; Nicole C Johnson; Michelle Y Alfonso; Nancy E Lowell; Patricia A Kruk
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.